Anti-CD40 [chi220]

Absolute Antibody

Anti-CD40 [chi220]

7

This antibody binds the CD40 and blocks the humoral immune responses to T cell dependent antigens in a dose dependent manner.

This antibody blocks the interaction between CD40 and gp39. Chi220 was used either alone or in combination with CTLA4-Ig in an immunosuppresive therapy study to check the survival of renal allografts in non human primate models (PMID: 12394833). Chi220 blocks binding of CD154, it also has partial agonist properties and weak stimulatory potential. It synergisticaly works with LEA29Y (belatacept) to prolong the islet allograft survival in a non-human primate Macaca fascicularis (PMID: 15611281). A study on protection of islets xenographs in diabetic macaques used a combination of Chi220 with IL-2 receptor specific antibody Basiliximab for immunosuppression with induction therapy. Chi220 is used as an sCD154 blocking agent and it was seen that it binds sCD154 in a dose dependant manner (PMID: 21920020). Two humanized versions of this antibody were generated F4 and L3.17, also showed similar properties. Humanized versions of this antibody are available on request.

Neutralisation/Blocking

Block; Therapeutic

Research Use Only

Monoclonal

chi220

CD40LG

CD40 ligand

CD154; CD40 antigen ligand; CD40 ligand; CD40L; CD40-L; gp39; hCD40L; HIGM1; IGM; IMD3; T-B cell-activating molecule; T-BAM; T-cell antigen Gp39; TNF-related activation protein; TNFSF5; TRAP; tumor necrosis factor (ligand) superfamily member 5

Human

IgG1

CD40 ligand

This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG2a format, for improved compatibility with existing reagents, assays and techniques.

Human

Human

This antibody was generated by immunizing female BALB/c mice with a fusion protein containing extracellular domain of human CD40 fused to the hinge CH2 and CH3 domains of a murine IgG2b antibody.

-20°C,2°C to 8°C

12352203